Adaptive designs for identifying optimal biological dose for molecularly targeted agents.
about
Implementation of adaptive methods in early-phase clinical trials.A Phase I/II adaptive design for heterogeneous groups with application to a stereotactic body radiation therapy trial.A Phase I/II adaptive design to determine the optimal treatment regimen from a set of combination immunotherapies in high-risk melanomaDose Titration Algorithm Tuning (DTAT) should supersede 'the' Maximum Tolerated Dose (MTD) in oncology dose-finding trials.Adaptive clinical trial designs in oncology.An Escalation for Bivariate Binary Endpoints Controlling the Risk of Overtoxicity (EBE-CRO): Managing Efficacy and Toxicity in Early Oncology Clinical Trials.Phase I/II dose-finding design for molecularly targeted agent: Plateau determination using adaptive randomization.STEIN: A simple toxicity and efficacy interval design for seamless phase I/II clinical trials.Keyboard: A Novel Bayesian Toxicity Probability Interval Design for Phase I Clinical Trials.A robust two-stage design identifying the optimal biological dose for phase I/II clinical trials.Extensions of the mTPI and TEQR designs to include non-monotone efficacy in addition to toxicity for optimal dose determination for early phase immunotherapy oncology trials.Design considerations for early-phase clinical trials of immune-oncology agentsOverall success rate of a safe and efficacious drug: Results using six phase 1 designs, each followed by standard phase 2 and 3 designs
P2860
Q30277243-4B6FFB17-0000-4F7D-ADF8-8A6A43B7594FQ30299964-EC080B50-9B47-48EA-B79C-41F3B69CFE4AQ30300873-816E89CC-C0C7-4F2B-B4F4-05834D384561Q33806551-01CE5B6C-2CB7-4E70-BDC6-4390C8BE2ADBQ35206844-6B854EED-F5A6-4690-B9C5-774243854BB1Q38735192-2F6D5362-4501-48E3-A26A-85E5F1CE4A76Q39910979-597B6F1F-DB09-4B4A-B4F5-D5BDB39A34D3Q48275752-C64B848D-0BDF-4EEE-B91B-2E5582BA042DQ53265989-F1FC48A0-BB62-4C84-9D5A-6375FA72F4EAQ55069897-CA841E7F-921D-435E-B25A-A45EBD7A88C5Q55123242-A065EC8D-1A88-4004-B573-0803D5FBB1E5Q56334001-172B8B2C-942C-4283-A056-1C65D09F64DEQ58704560-4A8CF0C8-024C-402A-9179-6F10EF03C3A0
P2860
Adaptive designs for identifying optimal biological dose for molecularly targeted agents.
description
2014 nî lūn-bûn
@nan
2014 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Adaptive designs for identifying optimal biological dose for molecularly targeted agents.
@ast
Adaptive designs for identifying optimal biological dose for molecularly targeted agents.
@en
Adaptive designs for identifying optimal biological dose for molecularly targeted agents.
@nl
type
label
Adaptive designs for identifying optimal biological dose for molecularly targeted agents.
@ast
Adaptive designs for identifying optimal biological dose for molecularly targeted agents.
@en
Adaptive designs for identifying optimal biological dose for molecularly targeted agents.
@nl
prefLabel
Adaptive designs for identifying optimal biological dose for molecularly targeted agents.
@ast
Adaptive designs for identifying optimal biological dose for molecularly targeted agents.
@en
Adaptive designs for identifying optimal biological dose for molecularly targeted agents.
@nl
P2093
P2860
P356
P1433
P1476
Adaptive designs for identifying optimal biological dose for molecularly targeted agents.
@en
P2093
P2860
P304
P356
10.1177/1740774514529848
P577
2014-05-20T00:00:00Z